Postmarketing surveillance for drug safety: Surely we can do better

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 6, 2004, Pages 491-494

  Griffin, Marie R ^a   Stein, C Michael ^b   Ray, Wayne A ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; GEMFIBROZIL; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; ROSIGLITAZONE; SALAZOSULFAPYRIDINE; TROGLITAZONE;

CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INFORMATION; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FLUID RETENTION; HEART FAILURE; HUMAN; LICENSING; LIVER TOXICITY; NOTE; PARESTHESIA; PATIENT; PEPTIC ULCER; PERIPHERAL NEUROPATHY; POPULATION RESEARCH; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SYMPTOM; TREATMENT CONTRAINDICATION;

ANTIRHEUMATIC AGENTS; DRUG THERAPY; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 2942565990     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.01.017     Document Type: Note

References (19)

1. Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004;75:580-5
2. Approval package Arava. Medical review, pt 2, Table 8. Available from: URL: http://www.fda.gov/cder/foi/nda/98/20905_arava.htm. Accessed April 20, 2004
3. Carulli M.T., Davies U.M. Peripheral neuropathy an unwanted effect of leflunomide? Rheumatology. 41:2002;952-953
4. Report to Congress. Reports on postmarketing studies (FDAMA 130). Available from: URL: http://www.fda.gov/cber/fdama/pstmrktfdama130.pdf. Accessed April 20, 2004
5. Postmarketing study commitments Arava. Available from: URL: http://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm. Accessed April 20, 2004
6. Stern R.S. A promising step forward in psoriasis therapy. JAMA. 290:2003;3133-3135
7. The Centers for Education and Research on Therapeutics (CERTs) Risk Assessment Workshop Participants. Risk assessment of drugs, biologics and therapeutic devices present and future issues. Pharmacoepidemiol Drug Saf. 12:2003;653-662
8. Mitchell A.A. Systematic identification of drugs that cause birth defects. A new opportunity. N Engl J Med. 349:2003;2556-2559
9. Wood A.J., Stein C.M., Woosley R. Making medicines safer - the need for an independent drug safety board. N Engl J Med. 339:1998;1851-1854
10. Ray W.A., Griffin M.R., Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med. 329:1993;2029-2032
11. Fries J.F. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 341:1999;1397-1398
12. Smalley W., Stein M., Eisen G., Ray W.A., Griffin M.R. Underutilization of gastroprotective measures in patients receiving nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 46:2002;2195-2200
13. Ubel P.A., Jepson C., Asch D.A. Misperceptions about β-blockers and diuretics. J Gen Intern Med. 18:2003;977-983
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 288:2002;2981-2997
15. Gale E.A.M. Lessons from the glitazones a story of drug development. Lancet. 357:2001;1870-1875
16. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure. Circulation. 108:2003;2941-2948
17. Farmer J.A. Learning from the cerivastatin experience. Lancet. 358:2001;1383-1385
18. Schiff G.D., Keehr L.M., Sai T.T., Bult J. High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic. Pharmacoepidemiol Drug Saf. 11:2002;643-645
19. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. [letter] N Engl J Med. 346:2002;539-540